R Jake Jacobs1, Allen S Meyerhoff. 1. Capitol Outcomes Research, Inc, Alexandria, VA 22310, USA. jake.jacobs@capitaloutcomesresearch.com
Abstract
BACKGROUND: Many patients seen at U.S. sexually transmitted disease (STD) clinics are offered hepatitis B vaccination. Substituting hepatitis A/B vaccine would provide additional protection but increase costs. GOAL: The goal was to estimate the cost effectiveness of hepatitis A/B versus B vaccination for 1,000,000 public STD clinic attenders. STUDY DESIGN: A Markov model of hepatitis A outcomes was developed using published literature, U.S. government databases, and expert panel opinion. Added vaccination costs were compared with savings from reduced hepatitis A treatment. Net costs were compared with life-years saved and quality-adjusted life-years (QALYs) gained. RESULTS: Substituting hepatitis A/B vaccine would prevent 2263 overt hepatitis A infections, 292 hospitalizations, 8 premature deaths, and the loss of 281 QALYs. Net health system costs would be $20,892 per life-year saved, or $13,397 per QALY gained. CONCLUSION: Substituting hepatitis A/B for hepatitis B vaccine would reduce morbidity and mortality in a cost-effective manner.
BACKGROUND: Many patients seen at U.S. sexually transmitted disease (STD) clinics are offered hepatitis B vaccination. Substituting hepatitis A/B vaccine would provide additional protection but increase costs. GOAL: The goal was to estimate the cost effectiveness of hepatitis A/B versus B vaccination for 1,000,000 public STD clinic attenders. STUDY DESIGN: A Markov model of hepatitis A outcomes was developed using published literature, U.S. government databases, and expert panel opinion. Added vaccination costs were compared with savings from reduced hepatitis A treatment. Net costs were compared with life-years saved and quality-adjusted life-years (QALYs) gained. RESULTS: Substituting hepatitis A/B vaccine would prevent 2263 overt hepatitis A infections, 292 hospitalizations, 8 premature deaths, and the loss of 281 QALYs. Net health system costs would be $20,892 per life-year saved, or $13,397 per QALY gained. CONCLUSION: Substituting hepatitis A/B for hepatitis B vaccine would reduce morbidity and mortality in a cost-effective manner.
Authors: Andrea M Anonychuk; Andrea C Tricco; Chris T Bauch; Ba' Pham; Vladimir Gilca; Bernard Duval; Ava John-Baptiste; Gloria Woo; Murray Krahn Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981
Authors: Xu-Sheng Zhang; Jason J Ong; Louis Macgregor; Tatiana G Vilaplana; Simone T Heathcock; Miranda Mindlin; Peter Weatherburn; Ford Hickson; Michael Edelstein; Sema Mandal; Peter Vickerman Journal: Lancet Reg Health Eur Date: 2022-06-17